F J Drummond1, E Barrett, R Burns, C O'Neill, L Sharp. 1. National Cancer Registry Ireland, Building 6800, Airport business Park, Kinsale Road, Cork, Ireland, f.drummond@ncri.ie.
Abstract
BACKGROUND: Ireland had the highest incidence of prostate cancer in Europe in 2008, due to widespread prostate specific antigen (PSA) testing. AIMS: To investigate practices and costs of PSA testing in Ireland, 2008-2010. METHODS: Postal laboratory questionnaire. Results were compared with 2006 and 2007 surveys. RESULTS: Response rate was 95 % (42/44). In 2010, 37 laboratories measured total PSA (tPSA); 10 measured free PSA (fPSA). Eight assays were used and cut-offs to define 'normal' tPSA varied widely. There was a 9.9 % annual increase in the number of tPSA tests and a -31 % annual decrease in the number of fPSA, 2006-2010. A 100-fold difference in tPSA workload was observed across laboratories. In 2010, the estimated cost of PSA testing was <euro>3,649,984 (95 % CI <euro>2,532,745-<euro>4,767,222). CONCLUSIONS: Health service costs of PSA testing are significant. The number of tPSA tests continues to rise; fPSA use fell by almost one-third. Inter-laboratory variation in testing practices persists. These have potentially important clinical consequences for men and need to be addressed.
BACKGROUND: Ireland had the highest incidence of prostate cancer in Europe in 2008, due to widespread prostate specific antigen (PSA) testing. AIMS: To investigate practices and costs of PSA testing in Ireland, 2008-2010. METHODS: Postal laboratory questionnaire. Results were compared with 2006 and 2007 surveys. RESULTS: Response rate was 95 % (42/44). In 2010, 37 laboratories measured total PSA (tPSA); 10 measured free PSA (fPSA). Eight assays were used and cut-offs to define 'normal' tPSA varied widely. There was a 9.9 % annual increase in the number of tPSA tests and a -31 % annual decrease in the number of fPSA, 2006-2010. A 100-fold difference in tPSA workload was observed across laboratories. In 2010, the estimated cost of PSA testing was <euro>3,649,984 (95 % CI <euro>2,532,745-<euro>4,767,222). CONCLUSIONS: Health service costs of PSA testing are significant. The number of tPSA tests continues to rise; fPSA use fell by almost one-third. Inter-laboratory variation in testing practices persists. These have potentially important clinical consequences for men and need to be addressed.
Authors: James C Forde; Laure Marignol; Ophelia Blake; Ted McDermott; Ronald Grainger; Vivien E Crowley; Thomas H Lynch Journal: BJU Int Date: 2012-02-16 Impact factor: 5.588
Authors: Andrew W Roddam; Michael J Duffy; Freddie C Hamdy; Anthony Milford Ward; Julietta Patnick; Christopher P Price; Janet Rimmer; Cathie Sturgeon; Peter White; Naomi E Allen Journal: Eur Urol Date: 2005-09 Impact factor: 20.096
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Alison M Pearce; Fay Ryan; Frances J Drummond; Audrey Alforque Thomas; Aileen Timmons; Linda Sharp Journal: Support Care Cancer Date: 2015-08-06 Impact factor: 3.603